ESMO 2021 | ST101: targeting C/EBPβ in patients with advanced solid tumors
Meredith A. McKean, MD, MPH, Sarah Cannon Research Institute, Nashville, TN, discusses the efficacy, safety and pharmacokinetic and pharmacodynamic data from a Phase I dose-escalation study of a novel therapeytic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients with advanced and metastatic solid tumors. ST101 has been demonstrated to induce selective cancer cell cytotoxicity across a variety of tumor types, including but not limited to breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Disclosures
Dr McKean reports research grants paid to Institution from Acentage Pharma Group, Bicycle Therapeutics, Dragonfly Therapeutics, Epizyme, Exelixis, Genentech, GlaxoSmithKline, IDEAYA Biosciences, Ikena Oncology, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Moderna, NBE Therapeutics, Novartis, Oncorus, Plexxikon, Prelude Therapeutics, Regeneron, Sapience Therapeutics, Seattle Genetics, Tizona Therapeutics, TMUNITY Therapeutics, TopAlliance Biosciences, Bayer, BioMed Valley Discoveries, EMD Serono, MedImmune, Nektar Therapeutics, Pfizer, Teneobio, Arvinas, Tempest Therapeutics, Arcus Biosciences, Synthrox, Alpine Immune, Scholar Rock, BioNTech, Erasca, Kechow Pharma, Mereo BioPharma, Foghorn Therapeutics, Pyramid Biosciences, PACT pharma, ImmVira Pharma, Kinnate Biopharma, Metabomed/
Dr McKean reports consulting/advisory roles from Array BioPharma, AstraZeneca, MedPage Today, Pfizer, Regeneron Pharmaceuticals, Astellas Pharma, BicycleTx Limited, Castle Biosciences, Ideaya Biosciences, iTeos.
